Novel helix-constrained nociceptin derivatives are potent agonists and antagonists of ERK phosphorylation and thermal analgesia in mice

Rosemary S. Harrison, Gloria Ruiz-Gómez, Timothy A. Hill, Shiao Y. Chow, Nicholas E. Shepherd, Rink Jan Lohman, Giovanni Abbenante, Huy N. Hoang, David P. Fairlie

Research output: Contribution to journalArticlepeer-review

Abstract

The nociceptin opioid peptide receptor (NOP, NOR, ORL-1) is a GPCR that recognizes nociceptin, a 17-residue peptide hormone. Nociceptin regulates pain transmission, learning, memory, anxiety, locomotion, cardiovascular and respiratory stress, food intake, and immunity. Nociceptin was constrained using an optimized helix-inducing cyclization strategy to produce the most potent NOP agonist (EC50 = 40 pM) and antagonist (IC50 = 7.5 nM) known. Alpha helical structures were measured in water by CD and 2D 1H NMR spectroscopy. Agonist and antagonist potencies, evaluated by ERK phosphorylation in mouse neuroblastoma cells natively expressing NOR, increased 20-fold and 5-fold, respectively, over nociceptin. Helix-constrained peptides with key amino acid substitutions had much higher in vitro activity, serum stability, and thermal analgesic activity in mice, without cytotoxicity. The most potent agonist increased hot plate contact time from seconds up to 60 min; the antagonist prevented this effect. Such helix-constrained peptides may be valuable physiological probes and therapeutics for treating some forms of pain.

Original languageEnglish
Pages (from-to)8400-8408
Number of pages9
JournalJournal of Medicinal Chemistry
Volume53
Issue number23
DOIs
Publication statusPublished - 9 Dec 2010

Fingerprint Dive into the research topics of 'Novel helix-constrained nociceptin derivatives are potent agonists and antagonists of ERK phosphorylation and thermal analgesia in mice'. Together they form a unique fingerprint.

Cite this